Calithera Biosciences (NASDAQ: CALA) reported Q4 EPS of ($0.31), $0.09 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $7.25 million versus the consensus estimate of $5.46 million.

For earnings history and earnings-related data on Calithera Biosciences (CALA) click here.